'Milestone' research at ESMO 22 offers new understanding of cancer

With the final presentations of this year’s meeting of the European Society of Medical Oncology (ESMO 22) in full swing, there is a lot for the scientific community to digest, including many potential catalysts for future research and development.

One such new focus for investment comes in the already heavily-researched area of lung cancer, a treatment setting which currently attracts in excess of $10 billion in revenues globally.

For many years, our approach to lung cancer has stemmed from an understanding that the primary driver of the disease is the inhalation of carcinogenic tobacco smoke.